Home›Trial›NCT06589310
NCT06589310RECRUITING

Falcon Real World Evidence Registry

Study Summary

This is a multi-site registry of patients receiving the Exact Sciences Multicancer Early Detection (MCED) test.

Conditions
Cancer
Interventions / Drugs
Exact Sciences Multicancer Early Detection (MCED) Test
View on ClinicalTrials.gov ↗
Sponsor
EXAS
Exact Sciences
Diagnostics
D43/100
Study Details
Enrollment25000 participants
Primary Completion—
Lead SponsorExact Sciences Corporation
Data Retrieved2026-04-11 04:13:38.204224+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 25,000 participants
Sponsor Catalyst Profile

Exact Sciences (EXAS) is the sponsoring company for this trial. BiotechSign currently grades this company D (43/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

EXAS Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.